RUNX2 and breast cancer: In breast cancer, RUNX2 and FOXM1 induce EMT and are regulated by sumoylation [51], and they share DNA binding sites in ERα; this association leads to the activation of genes involved in proliferation and metastasis and the development of endocrine resistance during tamoxifen treatment [52].